Skip to content
Home/Companies/Biotech/Mediar Therapeutics
MT

Mediar Therapeutics

Biotech·US·Active·5yr hold

Mediar Therapeutics is a healthcare / biotech company, headquartered in United States.

Entry
2021
Hold
5yr
Status
Active
Est. EV
–

Who owns Mediar Therapeutics?

Mediar Therapeutics is currently owned by Sofinnova Partners through Sofinnova Capital X (2021 vintage), since 2021. Across its history, Mediar Therapeutics has been through 2 private equity ownership periods, detailed in the timeline below.

Hand-verified · updated 2026-04-21

Sofinnova Partners
Most recent investor
Sofinnova Partners
Sofinnova Capital X · 2021 · Life Sciences VC
2 ownership periods · full history below

Key facts

HQUnited States
SectorHealthcare / Biotech

Ownership history

2 ownership periods · co-invest detected

Active
Co-held by Sofinnova Partners and Gimv since 2021.
Co-invest · 2 holders · 2021 · present
Sofinnova Partners
Sofinnova PartnersActive
2021 · present · Sofinnova Capital X · 2021 · Life Sciences VC
MOIC
–
Gimv
GimvActive
2021 · present · Gimv Portfolio
MOIC
–

More from Sofinnova Capital X

Other portfolio companies in the same fund.

DISCO Pharmaceuticals
Active
BiotechGermany· 2023
Freya Biosciences
Active
BiotechDenmark· 2023
May Health
Active
MedTechFrance· 2023
Nuage Therapeutics
Active
BiotechSpain· 2023
T-Therapeutics
Active
BiotechUK· 2023
Catamaran Bio
Active
BiotechUS· 2022

More PE-backed in Biotech

Comparable biotech deals from other GPs.

InBrain Pharma
Active
Finovam GestionFrance
Isavy Biotech
Active
Ring CapitalFrance
NeoVacs
Active
Odyssée VentureFrance
ReNeuron Group
Exited 2024
Obotritia CapitalUnited Kingdom
Univercells
Exited 2023
AdBio PartnersBelgium
to
2NA FISH
Active
Gruenderfonds RuhrGermany· 2026
Data refreshed weekly · Sourced from public filings